The study team calls or emails the registrant to explain the study and the consent process. Registering does not enroll a patient, and there is no obligation to take part.

Yes. A family member or caregiver can register on a patient’s behalf and becomes the study team’s point of contact. The Cancer Commons Participation and Consent Agreement must be accepted by the patient or the patient’s legally authorized representative.

Treatment guidelines, such as those published by the National Comprehensive Cancer Network (NCCN), list the treatments recommended for each cancer type. “Off-guideline” describes treatments not listed for a patient’s cancer type. The study reviews test results and published research for possible options in this group.

A drug sensitivity test exposes a sample of living tumor cells to a panel of cancer treatments in a laboratory and measures how the cells respond. Some tests use imaging and AI analysis. Laboratory results are one input to the scientific review and do not guarantee how a patient will respond to treatment.

No. The oncologist makes every treatment decision. Cancer Commons provides scientific analysis: it reviews test results and published research and reports possible treatment options, with the supporting evidence, to the oncologist. The report may also support the oncologist’s requests for insurance coverage.

Cancer Commons provides its scientific analysis at no charge. Testing costs vary by test provider. Treatment may be paid through insurance, compassionate use programs or other routes, and coverage is not guaranteed. The study team discusses potential costs before enrollment and works with the patient and oncologist on payment options.

There is no study site. Participants stay with their own oncologist at their own treatment center, anywhere in the United States. Cancer Commons works with participants by phone and email, and any testing is coordinated by email.

Many clinical studies test an investigational treatment and may require travel, randomization or a placebo. This is an observational study and does not include an investigational drug or travel to a study site. All treatment decisions are still made by the patient's own Oncologist. The study records outcomes to measure which tests best predict treatment response.